Trials / Completed
CompletedNCT00546143
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizumab | |
| DRUG | Omalizumab | |
| DRUG | Omalizumab |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-08-01
- First posted
- 2007-10-18
- Last updated
- 2010-09-02
Locations
5 sites across 2 countries: Germany, South Africa
Source: ClinicalTrials.gov record NCT00546143. Inclusion in this directory is not an endorsement.